HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda November 5, 2024
Ph 3 Trial of Adjuvant V940 (mRNA-4157) + KEYTRUDA After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of NSCLC Initiated November 5, 2024
FAILED TRIAL: Ph 2/3 Study of Uproleselan Did Not Meet Primary Endpoint of EFS improvement in elderly 1L AML patients November 5, 2024
FDA Regenerative Medicine Advanced Therapy (RMAT) Designation granted to ALLO-316 for Adult Patients with Advanced or Metastatic RCC November 5, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Gen Cancer Biotherapeutics November 5, 2024
Ph 2 Study of Masofaniten + Enzalutamide in metastatic CRPC Patients terminated; efficacy signals observed will not achieve target product profile November 5, 2024
Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Completed November 5, 2024
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals November 5, 2024
Revitope Enters into a License Agreement with Genmab for Next-gen T Cell Engagement Technology November 5, 2024
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Gen ADC Platform November 5, 2024
First Patient Dosed in Ph 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers November 5, 2024
AKIR001 cleared to start Ph 1 clinical trial in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, SCCHN, and NSCLC November 5, 2024
Ph 1b Clinical Trial expanded to Evaluate TTX-080 in Combination with Cetuximab and Chemotherapy in Advanced Colorectal Cancer November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab + Ligufalimab for 1L Treatment of HNSCC Compared to Pembrolizumab November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab Combination as 1L Therapy for Biliary Tract Tumors, Compared to Durvalumab November 5, 2024
Three Ph 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous NSCLC November 5, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented November 5, 2024
Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released November 5, 2024
Highly Significant Results In Ph 3 Study Of Ameluz®-Photodynamic Therapy (PDT) in Superficial Basal Cell Carcinoma (sBCC) Announced November 5, 2024
